Clopidogrel Aurobindo 75mg film-coated Tablets Malta - inglês - Medicines Authority

clopidogrel aurobindo 75mg film-coated tablets

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - clopidogrel - film-coated tablet - clopidogrel 75 mg - antithrombotic agents

Clopidogrel Vale Pharmaceuticals 75mg Film-Coated Tablets Malta - inglês - Medicines Authority

clopidogrel vale pharmaceuticals 75mg film-coated tablets

vale pharmaceuticals limited 3 anglesea street, clonmel, co. tipperary, e91 d6c5, ireland - clopidogrel - film-coated tablet - clopidogrel 75 mg - antithrombotic agents

ClopiVale 75mg Film-Coated Tablets Malta - inglês - Medicines Authority

clopivale 75mg film-coated tablets

vale pharmaceuticals limited 3 anglesea street, clonmel, co. tipperary, e91 d6c5, ireland - clopidogrel - film-coated tablet - clopidogrel 75 mg - antithrombotic agents

Clopval 75mg Film-Coated Tablets Malta - inglês - Medicines Authority

clopval 75mg film-coated tablets

vale pharmaceuticals limited 3 anglesea street, clonmel, co. tipperary, e91 d6c5, ireland - clopidogrel - film-coated tablet - clopidogrel 75 mg - antithrombotic agents

Clova 75mg Film-Coated Tablets Malta - inglês - Medicines Authority

clova 75mg film-coated tablets

vale pharmaceuticals limited 3 anglesea street, clonmel, co. tipperary, e91 d6c5, ireland - clopidogrel - film-coated tablet - clopidogrel 75 mg - antithrombotic agents

Clopidogrel 1A Pharma União Europeia - inglês - EMA (European Medicines Agency)

clopidogrel 1a pharma

acino pharma gmbh  - clopidogrel - peripheral vascular diseases - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome:- non st segment elevation acute coronary syndrome (unstable angina or non q wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa).- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.

Clopidogrel Acino União Europeia - inglês - EMA (European Medicines Agency)

clopidogrel acino

acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome., ,

Clopidogrel Acino Pharma União Europeia - inglês - EMA (European Medicines Agency)

clopidogrel acino pharma

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

Clopidogrel Acino Pharma GmbH União Europeia - inglês - EMA (European Medicines Agency)

clopidogrel acino pharma gmbh

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.for further information please refer to section 5.1.

Clopidogrel Hexal União Europeia - inglês - EMA (European Medicines Agency)

clopidogrel hexal

acino pharma gmbh - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;patients suffering from acute coronary syndrome:- non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);- st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.for further information please refer to section 5.1.